Natural History of Spinal Muscular Atrophy Type 1 in Taiwan

Overview

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations of the survival motor neuron 1 (SMN1) gene. The investigators will conduct a systematic review of the contents and activities collected via a comprehensive case report form. Patients who fulfilled diagnostic criteria for SMA type 1 will be reviewed retrospectively.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2015

Detailed Description

The primary objective of this study is to investigate the natural history of patients with spinal muscular atrophy (SMA) type 1 in Taiwan. This study will provide further insights into the clinical course and pathogenesis of SMA. Several analyses will be conducted regarding overall survival, respiratory support, feeding and nutritional support. The following outcome variables will be examined: correlation between SMA genotype and phenotype, survival, age of onset, and age of confirmed diagnosis, proportion of patients using non-invasive and invasive respiratory support, time to first use of respiratory support, proportion of patients on permanent ventilation, and time to permanent ventilation, number and average duration of hospitalizations, proportion of patients with gastrostomy, number of non-serious and serious respiratory infections, trend of growth parameter (e.g., body weight).

Arms, Groups and Cohorts

  • type 1 spinal muscular atrophy
    • The age of onset of patients with type 1 SMA is below 6 months of age.

Clinical Trial Outcome Measures

Primary Measures

  • Age of death
    • Time Frame: up to 36 years
    • participants will be followed till the age of death

Secondary Measures

  • Age of permanent ventilation
    • Time Frame: up to 36 years
    • participants will be followed till ventilation used 24 hours/day

Participating in This Clinical Trial

Inclusion Criteria

  • Jan. 1979~ 30 Jun. 2014 diagnosed with Spinal Muscular Atrophy (SMA)Type 1 – Onset of paralytic floppy infant less than 6 months of age – Generalized hypotonia and symmetric weakness, which weakness is more severe in proximal than distal part of extremities – Weakness in the legs is greater than in the arms – Tendon reflexes are absent – Neurogenic changes in electromyogram and/or muscle pathology – SMN1 gene deletion or mutation Exclusion Criteria:

  • Non-5q SMA (no deletion or mutation of SMN1 gene) – SMA type 2, type 3 or type 4 (onset of SMA after 6 months of age)

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 36 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Collaborator
    • Biogen
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.